scholarly journals Subsequent Ultrasound Vascular Targeting Therapy of Hepatocellular Carcinoma Improves the Treatment Efficacy

Biology ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 79
Author(s):  
Laith R. Sultan ◽  
Mrigendra B. Karmacharya ◽  
Stephen J. Hunt ◽  
Andrew K.W. Wood ◽  
Chandra M. Sehgal
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapy Group ◽  
Critical Role ◽  
Power Doppler ◽  
Doppler Imaging ◽  
Control Group ◽  
Ultrasound Therapy ◽  
Tumor Perfusion ◽  
Vascular Effect ◽  
Tumor Viability

The response of hepatocellular carcinoma (HCC) to anti-vascular ultrasound therapy (AVUS) can be affected by the inherent differences in tumor vascular structure, and the functionality of tumor vessels at the time of treatment. In this study, we evaluate the hypothesis that repeated subsequent AVUS therapies are a possible approach to overcome these factors and improve the therapeutic efficacy of AVUS. HCC was induced in 30 Wistar rats by oral ingestion of diethylnitrosamine (DEN) for 12 weeks. A total of 24 rats received treatment with low intensity, 2.8 MHz ultrasound with an intravenous injection of microbubbles. Treated rats were divided into three groups: single therapy group (ST), 2-days subsequent therapy group (2DST), and 7-days subsequent therapy group (7DST). A sham control group did not receive ultrasound therapy. Tumor perfusion was measured by quantitative contrast-enhanced ultrasound (CEUS) nonlinear and power-Doppler imaging. Tumors were harvested for histologic evaluation of ultrasound-induced vascular changes. ANOVA was used to compare the percent change of perfusion parameters between the four treatment arms. HCC tumors treated with 2DST showed the largest reduction in tumor perfusion, with 75.3% reduction on average for all perfusion parameters. The ST group showed an average decrease in perfusion of 54.3%. The difference between the two groups was significant p < 0.001. The 7DST group showed a reduction in tumor perfusion of 45.3%, which was significant compared to the 2DST group (p < 0.001) but not different from the ST group (p = 0.2). The use of subsequent targeted AVUS therapies applied shortly (two days) after the first treatment enhanced the anti-vascular effect of ultrasound. This gain, however, was lost for a longer interval (1 week) between the therapies, possibly due to tumor necrosis and loss of tumor viability. These findings suggest that complex interplay between neovascularization and tumor viability plays a critical role in treatment and, therefore, must be actively monitored following treatment by CEUS for optimizing sequential treatment.

Three-dimensional Power Doppler Imaging in Depicting Vascularity in Hepatocellular Carcinoma

2003 ◽  
Vol 22 (11) ◽  
pp. 1147-1154 ◽  
Author(s):  
Hui-Xiong Xu ◽  
Li Liu ◽  
Ming-De Lu ◽  
He-Ping Li ◽  
Guang-Jian Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Power Doppler ◽  
Three Dimensional ◽  
Doppler Imaging ◽  
Power Doppler Imaging

scholarly journals 3-D and Power Doppler Ultrasound in Translational Research

2009 ◽  
Vol 3 (4) ◽  
pp. 81-84
Author(s):  
Lakshmanaswamy Rajkumar
Keyword(s):  
Mammary Gland ◽  
Doppler Ultrasound ◽  
Power Doppler ◽  
Resistance Index ◽  
Doppler Imaging ◽  
Control Group ◽  
Power Doppler Ultrasound ◽  
Sprague Dawley ◽  
Medication Therapy ◽  
Mammary Gland Tumors

Abstract At Texas Tech University Health Sciences Center in El Paso we have developed an animal model to study mammary carcinogenesis and neovascularization. Seven-week-old female Sprague Dawley rats are injected with N-methyl-N-nitrosourea (MNU) intraperitoneally at a concentration of 50 mg/kg bodyweight. The rats are palpated twice a week for development of mammary gland tumors. On the appearance of the first palpable tumor, the animals are divided into the groups treated with aromatase inhibitor, ethanolic neem leaf extract and control group, receiving vehicle treatment. Using a high-resolution 16 MHz linear array transducer mammary glands are imaged before and every two weeks following the introduction of the therapy. 3-D US coupled with 3-D power Doppler imaging is used for evaluation of the volume and vascularity of the mammary gland lesions. Pulsatility and resistance index and vascularity, flow and vascularity flow indices are evaluated longitudinally. Our preliminary data indicate that 2-D and 3-D power Doppler ultrasound may be efficiently used for evaluation of the mammary gland tumor volumes and vascularity. 2-D and 3-D power Doppler ultrasound may also be used for evaluation of the response of mammary gland tumors to different lines of medication therapy.

scholarly journals Survival analysis of patients with medium and advanced hepatocellular carcinoma treated by TACE combined with Endostar

2020 ◽  
Vol 18 ◽  
pp. 205873922096055
Author(s):  
Xiu-Heng Qi ◽  
Zhen-Ming Wu ◽  
Qi Liu ◽  
Qian Guo ◽  
Ling-Ling Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapy Group ◽  
Hepatic Arterial Infusion ◽  
Progression Free Survival ◽  
Infusion Therapy ◽  
Control Group ◽  
Advanced Hepatocellular Carcinoma ◽  
Arterial Infusion ◽  
Advanced Hcc ◽  
The Difference

To explore the effects of two different administration routes of Endostar on the survival of patients with medium and advanced hepatocellular carcinoma (HCC) and underwent trans-arterial chemoembolization (TACE). Seventy-two patients with medium and advanced HCC were enrolled. Among them, 42 patients underwent the hepatic arterial infusion of Endostar combined with TACE (infusion therapy group); and the remaining 30 patients underwent the hepatic treatment of TACE combined with the intravenous application of Endostar (intravenous therapy group). All patients underwent regular examinations of CT (or MRI) and DSA to observe the conditions of tumor recurrence or metastasis, and to determine the existence of tumor angiogenesis. The response rate of treatment in the Endostar hepatic arterial infusion group was higher than that in the control group, and the difference was statistically significant (31/42:14/30, X2 = 5.501, p < 0.05). In addition, median progression free-survival time of the two groups were 8.67 months and 6.67 months, respectively ( p = 0.046); and the difference was statistically significant. The hepatic arterial infusion of Endostar combined with TACE can significantly improve recent clinical efficacy and mPFS in the treatment of medium and advanced HCC. However, improvement on the overall survival of long-term efficacy is not significant.

The long-term efficacy of cytokine-induced killer cellular therapy for hepatocellular carcinoma: a meta-analysis

Immunotherapy ◽  
2019 ◽  
Vol 11 (15) ◽  
pp. 1325-1335 ◽  
Author(s):  
Jiaxue Wang ◽  
Tiantian Shen ◽  
Qi Wang ◽  
Tan Zhang ◽  
Lujin Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Recurrence Rate ◽  
Randomized Clinical Trials ◽  
Cellular Therapy ◽  
Therapy Group ◽  
Meta Analysis ◽  
Control Group ◽  
Term Efficacy

Aim: The long-term efficacy of cytokine-induced killer cellular therapy for hepatocellular carcinoma patients after curative treatments remains controversial. Methods: A meta-analysis was conducted, and the outcomes were the recurrence rate and overall survival. Results: Eight randomized clinical trials with 1038 participants were included. Compared with the control group, cytokine-induced killer cellular therapy group could reduce 1-year, 3-year recurrence rates, as well as improve 1–5 years overall survival for hepatocellular carcinoma patients (p < 0.05). However, it failed to affect the 5-year recurrence rate and 6-year overall survival (p > 0.05). Conclusion: Cytokine-induced killer cellular adjuvant therapy exerted a favorable role in improving early and long-term efficacy for hepatocellular carcinoma patients.

Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis

Chemotherapy ◽  
2019 ◽  
Vol 64 (2) ◽  
pp. 94-104 ◽  
Author(s):  
Yan Wei ◽  
Jianjun Liu ◽  
Min Yan ◽  
Shuguang Zhao ◽  
Yong Long ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Transarterial Chemoembolization ◽  
Therapy Group ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Advanced Hepatocellular Carcinoma ◽  
Combination Therapy Group ◽  
Advanced Hcc

Background: The combination of transarterial chemoembolization (TACE) and apatinib has been used in the treatment of intermediate or advanced hepatocellular carcinoma (HCC). However, its effectiveness and safety are also argued. Methods: Eligible studies were collected from a computer search of literatures published from the database establishment to May 2019 in PubMed, Web of Science, EMBASE, Ovid, the Cochrane Library, Wanfang Database, China National Knowledge Infrastructure, and China Biology Medicine Disc. The objective response rate (ORR), the disease control rate (DCR), survival rate (SR), and the incidences of treatment-related adverse effects (AEs) were collected as the relevant outcomes. Data were analyzed through fixed/random effects of meta-analysis models with RevMan 5.3 software. Results: Eight randomized controlled clinical trials comprising 528 patients and 4 cohort studies comprising 226 patients were eventually included. Compared to the control group treated with TACE solely, combination therapy group, in which intermediate or advanced HCC patients were treated with TACE and apatinib, significantly enhanced ORR (relative risk [RR] 2.06, 95% CI 1.63–2.61, p < 0.001), DCR (RR 1.65, 95% CI 1.24–2.20, p < 0.001), and whole SRs of 6-month (RR 1.52, 95% CI 1.08–2.14, p = 0.02), 1-year (RR 1.52, 95% CI 1.25–1.84, p < 0.001), and 2-year (RR 1.84, 95% CI 1.34–2.54, p < 0.001). The incidence of hand foot syndrome, proteinuria, hypertension, and diarrhea was significantly increased in the combination therapy group compared with the control group (p < 0.05), and the incidence of nausea and vomiting, fever, and myelosuppression, respectively, was similar in 2 groups (p > 0.05). Conclusions: The combination therapy of TACE and apatinib can enhance the clinical effectiveness better than TACE solely in patients with intermediate or advanced HCC, while increase in the AEs is usually tolerable.

Sign in / Sign up

Export Citation Format

Share Document